Product News: Ciba Vision/Leiras Betimol
Ciba Vision/Leiras Betimol: Firms settle litigation with Merck involving branded version of ophthalmic beta blocker timolol and Ciba will continue to market the Leiras product under license from Merck. Leiras received a full NDA approval for timolol March 31; Merck has a patent on timolol that expires in March 1997. The three firms have agreed to dismiss pending litigation filed in Maryland federal court. Alcon received an ANDA for timolol in April; the company also obtained a license from Merck after litigation ("The Pink Sheet" May 8, 1995, T&G-16)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth